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Abstract 
Background: Recently women’s lung cancer mortality rates have dramatically increased in developed countries, 
contrasting with a levelling off or decrease among men. Descriptive epidemiological data on primary lung cancer in 
women is scarce in Morocco. The aim of this study, conducted in the National Institute of Oncology in Rabat, was to 
describe the epidemiological profiling especially for the smoking status, to determine the most frequent type of lung 
cancer, and to analyse the survival of Moroccan women with lung cancer diagnosis.
Results: We found 101 women among 1680 (male and female) cases of lung cancer. The never‑smokers were 
estimated to 75 %. The proportion of adenocarcinoma among never and passive smokers was higher than that of 
squamous cell carcinoma (SCC) (69.4 versus 30.6 %), while among women who were smokers, the most frequent 
histological type was SCC (63.6 %). The Cox regression analysis showed that smoking and passive smoking were not 
significantly associated with survival [HR: 0.62 (95 % CI 0.31, 1.30); p = 0.19] [HR: 0.56 (95 % CI 0.29, 1.08); p = 0.08] 
respectively. Adenocarcinoma was significantly associated with shorter survival [HR: 1.73 (95 % CI 1.05, 2.85); p = 0.03].
Conclusions: The majority Moroccan women affected by lung cancer have never smoked (75 %). Environmental 
exposures, genetic predisposition, hormonal factors, and viral infection may all play a role in lung cancer in this cat‑
egory. The relation between histological type and tobacco found in our series concurred with those reported in the 
literature—adenocarcinoma appears to be the most frequent cell type affecting never and passive smokers. Adeno‑
carcinoma is significantly associated with poorer survival.
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Background
In the United States, lung cancer has been the leading 
cause of cancer deaths in both men and women. It’s sur-
passed both breast cancer and colon cancer [1]. Despite 
the progress made in the last years in the diagnosis and 
treatment of this disease, men and women die each year 
from lung cancer. In recent years, lung cancer mortality 
rates in women have dramatically increased in developed 
countries, contrasting with a levelling off or decrease 
among men [2]. In women, this dramatic increase can be 
explained by multiple factors. The primary cause remains 
tobacco, which has rapidly gained social acceptance 
among women after World War II [3]. In contrast, the 
decrease of cancer mortality in men is probably attribut-
able to the decrease in smoking rates that began earlier in 
men than in women [3].
According to the Moroccan registry of cancer of Rabat 
of 2005, lung cancer is the leading cancer in men and 
comes at the eleventh place in women [4]. In Morocco, 
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a study conducted by Lalla Salma’s foundation: “Preven-
tion and Treatment of Cancer”, showed that over 15 years 
the prevalence of active smoking among elderly Moroc-
cans was estimated at 18  %, 31.5  % of which were men 
and 3.3 % were women. Moreover, 41 % of the population 
was exposed to passive smoking [5].
Purely descriptive epidemiological data on primary 
lung cancer in women are scarce in Morocco. The aim of 
this study, conducted in the National Institute of Oncol-
ogy in Rabat, was to describe the epidemiological profil-
ing, in particular the smoking status, to determine the 
most frequent type of lung cancer, and to analyse the sur-
vival of Moroccan women with lung cancer diagnosis.
Methods
A retrospective study was performed enrolling 1680 
cases of lung cancer, 101 (6  %) were women diagnosed 
between the period of January 2004 and December 2008 
at the National Institute of Oncology. All these incident 
cases were within the respective time period.
The study respected the ethical rules of medical 
research involving human subjects as stipulated by the 
World Medical Association in the Declaration of Hel-
sinki. The local ethical committee of the National Insti-
tute of Oncology of Rabat also approved this study; with 
the consentment of patients or their families.
The hospital charts, including medical history, were 
reviewed and the following information was collected: 
age at diagnosis, smoking status, histology, stage, pre-
senting symptoms, investigations, treatment (surgical 
resection, radiotherapy, chemotherapy, or no treatment) 
and survival.
All diagnosis were proved by anatomopathologic analy-
sis of biopsy specimen. Non small cell lung cancer was 
divided into adenocarcinoma, squamous cell carcinoma 
and large cell carcinoma.
The descriptive analysis was made by Statistical Pack-
age for the Social Science version 13.0 (SPSS). The pro-
gression free survival (PFS) was defined as the time from 
the start of treatment to the first documented disease 
progression or death from any cause. For PFS, Kaplan–
Meier curves were constructed and compared by using 
a long-rank test. Descriptive statistics with 95 % of con-
fidence interval were calculated according to standard 
procedure.
Results
We found 101 women among 1680 cases of lung cancer 
(versus 1579 men). The mean age was 55.68 years (stand-
ard deviation was 13.06).
The percentage of never-smokers was 75  %, 14  % of 
patients had an environmental tobacco smoke exposure 
(the husband or another person in the family who smoke) 
and 11 % reported personal smoking (Table 1). The most 
frequent mode of presentation was chest pain (60  %), 
cough (54  %), dyspnea (38  %) and hemoptysis (27  %). 
Proportion of non small cell lung cancer at stage IV was 
higher (82 %), 16 % of cases were at stage III and only 2 % 
were classified as stage II (Table 1).
The proportion of adenocarcinoma among never and 
passive smokers was higher than that of squamous cell 
carcinoma (69.4 versus 30.6 %), while among women who 
were smokers, the most frequent histological type was 
squamous cell carcinoma (63.6 %).
The median follow-up was 2  months (1–24  months). 
The histological diagnosis was based on biopsy during 
bronchoscopy (80  %), as well as biopsy guided by CT 
scan (16 %) or thoracotomy (4 %).
Palliative chemotherapy was planned in 43 % of cases, 7 % 
were treated by chemoradiation, 8 % by radiotherapy, 2 % 
Table 1 Patient characteristics
Cases Percentage
Smoking status
 Never smokers 76 75
 Passive smokers 14 14
 Smokers 11 11
Symptoms
 Dyspnea 38 38
 Chest pain 61 60
 Cough 55 54
 Hemoptysis 27 27
 Intracranial hypertension 7 6
 Vena cava syndrome 1 1
 Phlebitis of upper limb 1 1
Stage of non small cell lung cancer
 Stage IV 83 82
 Stage III 16 16
 Stage II 2 2
 Stage I 0 0
Lung cancer cell type
 Adenocarcinoma 60 59
 Squamous cell carcinoma 33 32
 Poorly differentiated carcinoma 1 1
 Small cell lung cancer 7 7
Treatment
 Palliative chemotherapy 43 43
 Chemoradiation 7 7
 Radiotherapy 8 8
 Neoadjuvant chemotherapy before chemoradia‑
tion
2 2
 Best supportive care 35 34
 Brain irradiation 4 4
 Surgery and radiotherapy 2 2
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received a neoadjuvant chemotherapy before chemoradia-
tion and 2 % were treated by surgery and radiotherapy. The 
best supportive care were proposed in 34  % of cases and 
4 % of patients received a whole brain irradiation (Table 1).
For follow-up cases (88  %), the survival rates of cases 
with no small cell lung cancer at 6 months were at 27.7 %. 
Cases with squamous cell carcinoma had higher survival 
rates than the ones with adenocarcinoma (44.4 versus 
25 %; p =  0.01), but we had no significant difference in 
progression free survival at 6 months between squamous 
cell carcinoma and adenocarcinoma (20 versus 25  %; 
p = 0.81) (Figs. 1, 2). In cases with small cell lung cancer, 
the survival rate at 6 months was 0 %. 13 cases were lost 
to follow-up.
The Cox regression analysis showed that smoking and 
passive smoking were not significantly associated with 
Fig. 1 Time to death, survival curve in terms of histological type
Fig. 2 Time to progression, survival curve in terms of histological type
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survival [HR: 0.62 (95  % CI 0.31, 1.30); p  =  0.19] [HR: 
0.56 (95 % CI 0.29, 1.08); p = 0.08] respectively.
Adenocarcinoma was significantly associated with 
poorer survival [HR: 1.73 (95 % CI 1.05, 2.85); p = 0.03], 
brain metastasis was not significantly associated with 
survival [HR: 1.01 (95 % CI 0.53, 1.93); p = 0.97].
Subgroup analysis (85 patients who were never or 
passive smokers) showed that there was no significant 
difference in survival at 6  months between squamous 
cell carcinoma and adenocarcinoma (35 versus 20  %; 
p = 0.08) (Table 2).
90.9  % (10 patients) of active smoking patients died, 
and one patient (accounting for 9.09 %) was lost to follow. 
85 % (12 patients) of passive smoking patients died and 
14.28 % (2 patients) were lost to follow.
Discussion
The mean age was 55.68  years (standard deviation was 
13.06). Our patients developed the disease at an earlier 
age than other women in other studies [6, 7].
In our study, the percentage of never-smokers was 
75  %. 14  % of patients had an environmental tobacco 
smoke exposure (the husband or another person in the 
family who smoke) and 11  % were reported personal 
smoking. In the majority of American and European 
reviews, most of the patients were current or ex-smokers 
[7–9]. Recently, approximately 23.1 % of men and 18.3 % 
of women in the United States have been cigarette smok-
ers so far [10].
Tobacco does not explain all the women cases with 
lung cancer, because in this study, 75 % of patients were 
never smokers. Multiple factors such as environmen-
tal exposures, genetic mutations, hormonal factors, and 
some infections have also been implicated in the develop-
ment of lung cancer in women who have never smoked 
[1]. A possible role of circulating steroid hormones par-
ticularly of oestrogens, in the etiology of lung cancer has 
been hypothesized [11]. It should be noted that oestrogen 
receptors have been detected on cancerous lung cells and 
estrogens induce the differentiation and maturation of 
the foetal lung [11–13]. Different studies have suggested 
that there is a potential protective effect of increased 
or prolonged estrogen exposure, others have found the 
opposite [14, 15].
Furthermore, a large meta-analysis reported a 24.5  % 
worldwide incidence of HPV in lung cancer, particularly 
in China [16] and recently, many Asian studies indicate 
that longer telomere length may increase lung cancer risk 
[17].
Studies evaluating gene environment interactions may 
provide important insights into carcinogenesis pathways 
of lung cancer in never smokers.
In European and American series, most cases of non-
small cell lung cancer were diagnosed at a relatively 
advanced stage according to the TNM classification sys-
tem [6]. In our population, proportion of non small cell 
lung cancer at stage IV was higher (82 %), 16 % of cases 
were at stage III and only 2 % were at stage II. This high 
percentage can be explained by the delay of diagnosis.
At the end of 1960s, changes in the frequency of dif-
ferent histological subtypes of lung cancer have been 
observed worldwide, with an increasing proportion of 
adenocarcinoma and a declining proportion of squa-
mous cell carcinoma [18]. In our study, the proportion 
of adenocarcinoma among never and passive smokers 
was higher than that of squamous cell carcinoma (69.4 
versus 30.6  %), while among women who were smok-
ers, the most frequent histological type was squamous 
cell carcinoma (63.6  %). These results are almost simi-
lar to those reported in other studies. Adenocarcinoma 
represented 68.1  % in the Mayo Clinic’ study, 71  % in 
the Bennet’s series and 43.4 % in the Grivaux study [6, 
9, 19].
Moreover, women’s 5-year relative survival rates have 
improved across nearly all stages with similar histologies, 
the benefit was more important in those with adenocar-
cinoma [20, 21]. In this study, adenocarcinoma was sig-
nificantly associated with poorer survival [HR: 1.73 (95 % 
CI 1.05, 2.85); p =  0.03], while in a Radzikowska study 
published in Annals of Oncology 2002, the squamous cell 
carcinoma was a negative predictor of survival in univari-
ate analysis (p = 0.008), but this result was no significant 
in multivariate analysis (p = 0.29) [7].
Lung cancer survival rates for non smokers have 
improved compared with those of smokers [22]. In this 
series, the Cox regression analysis showed that smoking 
and passive smoking were not significantly associated 
with survival [HR: 0.62 (95  % CI 0.31, 1.30); p  =  0.19] 
[HR: 0.56 (95 % CI 0.29, 1.08); p = 0.08] respectively. Even 
though HR are neither statistically significant for smok-
ing nor passive smoking, HR estimates seem to show a 
protective effect for tobacco smoking, which is highly 
unlikely. This may indicate some bias or confounding 
within the study population. However, the data does not 
allow additional analysis to understand these estimates.
Table 2 Subgroups analysis
Adenocarcinoma Associated with survival [HR: 1.73 (95 % CI 1.05, 
2.85); p = 0.03]
Smoking Not associated with 
survival
[HR: 0.62 (95 % CI 0.31, 
1.30); p = 0.19]
Passive smoking Not associated with 
survival
[HR: 0.56 (95 % CI 0.29, 
1.08); p = 0.08]
Brain metastasis Not associated with 
survival
[HR: 1.01 (95 % CI 0.53, 
1.93); p = 0.97]
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This study had potential limitations, one of which was 
the retrospective nature of the analysis. Definitely, a case 
control study with healthy controls would have been 
methodologically more powerful.
Conclusions
Many Moroccan women affected by lung cancer have 
never smoked (75 %). The relationships between histolog-
ical type and tobacco found in our series are in agreement 
with those reported in the literature: adenocarcinoma 
appears to be the most frequent cell type among never 
and passive smokers. Furthermore, adenocarcinoma is 
significantly associated with poorer survival.
Smoking does not explain all cases of lung cancer. Envi-
ronmental exposures, genetic predisposition, hormonal 
factors, and viral infection may all play a role in lung can-
cer in women.
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